Literature DB >> 31804972

Novel three-dimensional cultures provide insights into thyroid cancer behavior.

Mason A Lee1,2, Kensey N Bergdorf3, Courtney J Phifer1, Caroline Y Jones1, Sonia Y Byon1, Leah M Sawyer4, Joshua A Bauer5, Vivian L Weiss1.   

Abstract

Thyroid cancer has the fastest growing incidence of any cancer in the United States, as measured by the number of new cases per year. Despite advances in tissue culture techniques, a robust model for thyroid cancer spheroid culture is yet to be developed. Using eight established thyroid cancer cell lines, we created an efficient and cost-effective 3D culture system that can enhance our understanding of in vivo treatment response. We found that all eight cell lines readily form spheroids in culture with unique morphology, size, and cytoskeletal organization. In addition, we developed a high-throughput workflow that allows for drug screening of spheroids. Using this approach, we found that spheroids from K1 and TPC1 cells demonstrate significant differences in their sensitivities to dabrafenib treatment that closely model expected patient drug response. In addition, K1 spheroids have increased sensitivity to dabrafenib when compared to monolayer K1 cultures. Utilizing traditional 2D cultures of these cell lines, we evaluated the mechanisms of this drug response, showing dramatic and acute changes in their actin cytoskeleton as well as inhibition of migratory behavior in response to dabrafenib treatment. Our study is the first to describe the development of a robust spheroid system from established cultured thyroid cancer cell lines and adaptation to a high-throughput format. We show that combining 3D culture with traditional 2D methods provides a complementary and powerful approach to uncover drug sensitivity and mechanisms of inhibition in thyroid cancer.

Entities:  

Keywords:  actin; invasion; spheroid; thyroid carcinoma; β-catenin

Mesh:

Substances:

Year:  2020        PMID: 31804972      PMCID: PMC7295136          DOI: 10.1530/ERC-19-0374

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  24 in total

1.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Authors:  Marcia S Brose; Christopher M Nutting; Barbara Jarzab; Rossella Elisei; Salvatore Siena; Lars Bastholt; Christelle de la Fouchardiere; Furio Pacini; Ralf Paschke; Young Kee Shong; Steven I Sherman; Johannes W A Smit; John Chung; Christian Kappeler; Carol Peña; István Molnár; Martin J Schlumberger
Journal:  Lancet       Date:  2014-04-24       Impact factor: 79.321

Review 2.  Molecular mechanisms of epithelial-mesenchymal transition.

Authors:  Samy Lamouille; Jian Xu; Rik Derynck
Journal:  Nat Rev Mol Cell Biol       Date:  2014-03       Impact factor: 94.444

Review 3.  Actin assembly mechanisms at a glance.

Authors:  Klemens Rottner; Jan Faix; Sven Bogdan; Stefan Linder; Eugen Kerkhoff
Journal:  J Cell Sci       Date:  2017-10-15       Impact factor: 5.285

Review 4.  Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review.

Authors:  Roger T Anderson; John E Linnehan; Vanita Tongbram; Karen Keating; Lori J Wirth
Journal:  Thyroid       Date:  2013-04       Impact factor: 6.568

Review 5.  BRAF inhibitors: experience in thyroid cancer and general review of toxicity.

Authors:  M E Cabanillas; A Patel; B P Danysh; R Dadu; S Kopetz; G Falchook
Journal:  Horm Cancer       Date:  2014-12-03       Impact factor: 3.869

Review 6.  The way Wnt works: components and mechanism.

Authors:  Kenyi Saito-Diaz; Tony W Chen; Xiaoxi Wang; Curtis A Thorne; Heather A Wallace; Andrea Page-McCaw; Ethan Lee
Journal:  Growth Factors       Date:  2012-12-21       Impact factor: 2.511

7.  The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma.

Authors:  Jack McCain
Journal:  P T       Date:  2013-02

Review 8.  Thyroid cancer nodal metastases: biologic significance and therapeutic considerations.

Authors:  S K Grebe; I D Hay
Journal:  Surg Oncol Clin N Am       Date:  1996-01       Impact factor: 3.495

Review 9.  Organoid technology and applications in cancer research.

Authors:  Hanxiao Xu; Xiaodong Lyu; Ming Yi; Weiheng Zhao; Yongping Song; Kongming Wu
Journal:  J Hematol Oncol       Date:  2018-09-15       Impact factor: 17.388

Review 10.  Wnt Signaling in Thyroid Homeostasis and Carcinogenesis.

Authors:  Kim A Ely; Lindsay A Bischoff; Vivian L Weiss
Journal:  Genes (Basel)       Date:  2018-04-10       Impact factor: 4.096

View more
  5 in total

1.  Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids.

Authors:  Viktoria Koroknai; Vikas Patel; István Szász; Róza Ádány; Margit Balazs
Journal:  Pathol Oncol Res       Date:  2020-07-01       Impact factor: 3.201

2.  Obtaining patient-derived cancer organoid cultures via fine-needle aspiration.

Authors:  Courtney J Phifer; Kensey N Bergdorf; Matthew E Bechard; Anna Vilgelm; Naira Baregamian; Oliver G McDonald; Ethan Lee; Vivian L Weiss
Journal:  STAR Protoc       Date:  2020-12-21

3.  High-throughput drug screening of fine-needle aspiration-derived cancer organoids.

Authors:  Kensey Bergdorf; Courtney Phifer; Vijaya Bharti; David Westover; Joshua Bauer; Anna Vilgelm; Ethan Lee; Vivian Weiss
Journal:  STAR Protoc       Date:  2020-12-16

4.  Utilizing Three-Dimensional Culture Methods to Improve High-Throughput Drug Screening in Anaplastic Thyroid Carcinoma.

Authors:  Kensey Bergdorf; Joshua A Bauer; David Westover; Courtney Phifer; Barbara Murphy; Darren R Tyson; Ethan Lee; Vivian L Weiss
Journal:  Cancers (Basel)       Date:  2022-04-07       Impact factor: 6.575

5.  Immunofluorescent staining of cancer spheroids and fine-needle aspiration-derived organoids.

Authors:  Kensey N Bergdorf; Courtney J Phifer; Matthew E Bechard; Mason A Lee; Oliver G McDonald; Ethan Lee; Vivian L Weiss
Journal:  STAR Protoc       Date:  2021-05-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.